{"id":37504,"date":"2025-07-17T12:16:28","date_gmt":"2025-07-17T04:16:28","guid":{"rendered":"https:\/\/flcube.com\/?p=37504"},"modified":"2025-07-17T12:16:29","modified_gmt":"2025-07-17T04:16:29","slug":"konruns-kc1036-proposed-for-cdes-spark-program-to-accelerate-pediatric-ewings-sarcoma-treatment-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37504","title":{"rendered":"Konruns’ KC1036 Proposed for CDE’s SPARK Program to Accelerate Pediatric Ewing\u2019s Sarcoma Treatment Development"},"content":{"rendered":"\n

Beijing-based Konruns Pharmaceutical Co., Ltd. (SHA: 603590<\/a>) announced on Wednesday that China\u2019s Center for Drug Evaluation (CDE) has proposed adding its oral kinase inhibitor KC1036 to the Support Anti-tumor drugs R&D for Kids (SPARK) pilot program. This initiative aims to accelerate the development of treatments for pediatric Ewing\u2019s sarcoma. The public comment period for this proposal closes on July 23.<\/p>\n\n\n\n

About KC1036<\/strong>
KC1036 is a Category 1.1 small-molecule drug discovered in-house by Konruns. It works by simultaneously blocking VEGFR2 and AXL, thereby cutting off the blood supply to tumors and inhibiting their ability to evade the immune system. Konruns holds global intellectual property rights for this promising asset.<\/p>\n\n\n\n

SPARK Pilot Program<\/strong>
The SPARK pilot program is an extension of the patient-centric CARE scheme for rare diseases. It implements the National Medical Products Administration\u2019s (NMPA) mandate of \u201cearly engagement, one-company-one-policy, end-to-end guidance, integrated review.\u201d The program offers sponsors tailored support on development strategy, trial design, pediatric formulations, and dosing. This support is designed to shorten development timelines and improve access to medicines for rare childhood cancers.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Beijing-based Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced on Wednesday that China\u2019s Center for Drug…<\/p>\n","protected":false},"author":1,"featured_media":37505,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,4],"tags":[16,2984,15,1532],"class_list":["post-37504","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-policy-regulatory","tag-cancer","tag-konruns-pharmaceutical","tag-product-approvals","tag-sha-603590"],"yoast_head":"\nKonruns' KC1036 Proposed for CDE's SPARK Program to Accelerate Pediatric Ewing\u2019s Sarcoma Treatment Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing-based Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced on Wednesday that China\u2019s Center for Drug Evaluation (CDE) has proposed adding its oral kinase inhibitor KC1036 to the Support Anti-tumor drugs R&D for Kids (SPARK) pilot program. This initiative aims to accelerate the development of treatments for pediatric Ewing\u2019s sarcoma. The public comment period for this proposal closes on July 23.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37504\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Konruns' KC1036 Proposed for CDE's SPARK Program to Accelerate Pediatric Ewing\u2019s Sarcoma Treatment Development\" \/>\n<meta property=\"og:description\" content=\"Beijing-based Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced on Wednesday that China\u2019s Center for Drug Evaluation (CDE) has proposed adding its oral kinase inhibitor KC1036 to the Support Anti-tumor drugs R&D for Kids (SPARK) pilot program. This initiative aims to accelerate the development of treatments for pediatric Ewing\u2019s sarcoma. The public comment period for this proposal closes on July 23.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37504\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-17T04:16:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-17T04:16:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37504#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37504\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Konruns’ KC1036 Proposed for CDE’s SPARK Program to Accelerate Pediatric Ewing\u2019s Sarcoma Treatment Development\",\"datePublished\":\"2025-07-17T04:16:28+00:00\",\"dateModified\":\"2025-07-17T04:16:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37504\"},\"wordCount\":197,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37504#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1703.webp\",\"keywords\":[\"Cancer\",\"Konruns Pharmaceutical\",\"Product approvals\",\"SHA: 603590\"],\"articleSection\":[\"Company\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37504#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37504\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37504\",\"name\":\"Konruns' KC1036 Proposed for CDE's SPARK Program to Accelerate Pediatric Ewing\u2019s Sarcoma Treatment Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37504#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37504#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1703.webp\",\"datePublished\":\"2025-07-17T04:16:28+00:00\",\"dateModified\":\"2025-07-17T04:16:29+00:00\",\"description\":\"Beijing-based Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced on Wednesday that China\u2019s Center for Drug Evaluation (CDE) has proposed adding its oral kinase inhibitor KC1036 to the Support Anti-tumor drugs R&D for Kids (SPARK) pilot program. This initiative aims to accelerate the development of treatments for pediatric Ewing\u2019s sarcoma. The public comment period for this proposal closes on July 23.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37504#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37504\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37504#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1703.webp\",\"width\":1080,\"height\":608,\"caption\":\"Konruns' KC1036 Proposed for CDE's SPARK Program to Accelerate Pediatric Ewing\u2019s Sarcoma Treatment Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37504#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Konruns’ KC1036 Proposed for CDE’s SPARK Program to Accelerate Pediatric Ewing\u2019s Sarcoma Treatment Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Konruns' KC1036 Proposed for CDE's SPARK Program to Accelerate Pediatric Ewing\u2019s Sarcoma Treatment Development - Insight, China's Pharmaceutical Industry","description":"Beijing-based Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced on Wednesday that China\u2019s Center for Drug Evaluation (CDE) has proposed adding its oral kinase inhibitor KC1036 to the Support Anti-tumor drugs R&D for Kids (SPARK) pilot program. This initiative aims to accelerate the development of treatments for pediatric Ewing\u2019s sarcoma. The public comment period for this proposal closes on July 23.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37504","og_locale":"en_US","og_type":"article","og_title":"Konruns' KC1036 Proposed for CDE's SPARK Program to Accelerate Pediatric Ewing\u2019s Sarcoma Treatment Development","og_description":"Beijing-based Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced on Wednesday that China\u2019s Center for Drug Evaluation (CDE) has proposed adding its oral kinase inhibitor KC1036 to the Support Anti-tumor drugs R&D for Kids (SPARK) pilot program. This initiative aims to accelerate the development of treatments for pediatric Ewing\u2019s sarcoma. The public comment period for this proposal closes on July 23.","og_url":"https:\/\/flcube.com\/?p=37504","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-17T04:16:28+00:00","article_modified_time":"2025-07-17T04:16:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37504#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37504"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Konruns’ KC1036 Proposed for CDE’s SPARK Program to Accelerate Pediatric Ewing\u2019s Sarcoma Treatment Development","datePublished":"2025-07-17T04:16:28+00:00","dateModified":"2025-07-17T04:16:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37504"},"wordCount":197,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37504#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1703.webp","keywords":["Cancer","Konruns Pharmaceutical","Product approvals","SHA: 603590"],"articleSection":["Company","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37504#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37504","url":"https:\/\/flcube.com\/?p=37504","name":"Konruns' KC1036 Proposed for CDE's SPARK Program to Accelerate Pediatric Ewing\u2019s Sarcoma Treatment Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37504#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37504#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1703.webp","datePublished":"2025-07-17T04:16:28+00:00","dateModified":"2025-07-17T04:16:29+00:00","description":"Beijing-based Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced on Wednesday that China\u2019s Center for Drug Evaluation (CDE) has proposed adding its oral kinase inhibitor KC1036 to the Support Anti-tumor drugs R&D for Kids (SPARK) pilot program. This initiative aims to accelerate the development of treatments for pediatric Ewing\u2019s sarcoma. The public comment period for this proposal closes on July 23.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37504#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37504"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37504#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1703.webp","width":1080,"height":608,"caption":"Konruns' KC1036 Proposed for CDE's SPARK Program to Accelerate Pediatric Ewing\u2019s Sarcoma Treatment Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37504#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Konruns’ KC1036 Proposed for CDE’s SPARK Program to Accelerate Pediatric Ewing\u2019s Sarcoma Treatment Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1703.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37504"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37504\/revisions"}],"predecessor-version":[{"id":37506,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37504\/revisions\/37506"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37505"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}